Bioliberty, a healthtech startup focused on transforming physical and occupational therapy delivery, announced it has raised $10.2 million in financing to advance its functional intelligence capabilities for post-acute care. The funding will support continued development and U.S. commercialization of its Lifehub platform, including expanded computer vision and care coordination features, as well as the rollout of Lifehub Home to extend therapy and monitoring into patients’ homes.
The financing includes an $8.2 million Series A round led in part by a $4 million investment from the Scottish National Investment Bank, with participation from Archangels, Eos Advisory, Old College Capital, Hanna Capital SEZC, and new investor Conduit Connect. This follows a $2 million pre-Series A round completed in mid-2025.
Bioliberty’s Lifehub Clinic platform, launched in 2025, uses AI and robotics to monitor functional recovery and enhance therapy delivery in post-acute settings. The company reports growing adoption across major U.S. rehabilitation providers, including partnerships with one of the largest rehabilitation networks and Sheltering Arms Institute. The company is also collaborating with research organizations including Mount Sinai and the U.S. Department of Veterans Affairs.
The company aims to address a key gap in healthcare by providing objective functional mobility data, which is increasingly important in value-based care models. Accurate measurement of patient function is critical for reducing hospital readmissions and improving discharge planning. Bioliberty’s technology enables clinicians to track recovery, identify high-risk patients, and make data-driven care decisions.
As part of the financing, Russell Bailey, President of Lifepoint Rehabilitation, and Dana Prommel Strauss, Lead Director of Public Policy and Government Affairs at CVS Health, have joined Bioliberty’s Board of Directors, bringing additional expertise in post-acute care and healthcare policy.
Bioliberty has raised a total of $17.5 million since its founding in 2023 and holds multiple patents across its core technologies, including Lifehub and Lifeglov, both of which are FDA-registered.
KEY QUOTES
“Our team is pleased with the initial success of Lifehub Clinic in the U.S. market, helping post-acute care providers improve patient outcomes through intelligent therapy delivery and discharge planning that incorporates functional data. We look forward to leveraging the expertise of our expanded Board of Directors to further the impact of this work. With this investment, we are expanding how we measure functional recovery through computer vision and AI-driven assessments to build the predictive capability of our product, and to commercialize a system extending those insights into the home.”
Rowan Armstrong, Co-Founder And Chief Executive Officer Of Bioliberty
“Throughout my leadership career, I have evaluated numerous emerging technologies, and over the past year, Bioliberty has significantly stood out. The seamless integration into high-intensity clinical workflows and the generation of actionable data for teams have been remarkable. I’ve witnessed how the platform enhances clinical outcomes while providing care teams and leaders with the visibility needed to standardize care across an expanding post-acute network. I’m thrilled to support Bioliberty as they continue to scale and deliver exceptional value for providers, ultimately ensuring excellent quality outcomes for patients.”
Russell Bailey, President Of Lifepoint Rehabilitation
“The acceleration of value-based care and interoperability solutions have created an urgent demand for objective data that delivers actionable insights and predicts patient pathways to reduce the total cost of care. Bioliberty is enhancing physical and occupational therapists hands-on time with patients while capturing the ‘missing link’ of functional mobility data needed to improve discharge planning and reduce readmissions. These critical insights are what the post-acute space has been waiting for.”
Dana Prommel Strauss, Lead Director Of Public Policy And Government Affairs At CVS Health
